Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

SOHO 2023 | Pevonedistat, azacitidine and venetoclax triplet therapy for AML, MDS and CMML

Nicholas Short, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses the rationale and preliminary findings of a Phase I/II study (NCT03862157) investigating a triplet therapy of pevonedistat, azacitidine and venetoclax. This study enrolled patients with newly diagnosed secondary acute myeloid leukemia (AML), a historically poor-risk population, and patients with myelodysplastic syndromes (MDS) or chronic myelomonocytic leukemia (CMML) after failure of hypomethylating agents. The MDS/CMML arm was closed following the results of the Phase III PANTHER study (NCT03268954), but promising response rates were observed in the AML arm. This interview took place at the Eleventh Annual Meeting of the Society of Hematologic Oncology (SOHO 2023) held in Houston, TX.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.